The prognosis of breast cancer patients with bone metastasis could be potentially estimated based on blood routine test and biochemical examination at admission

References

• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):1–15. doi: 10.3322/caac.21660.
   Web of Science ®Google Scholar
• Xiong Z, Deng G, Huang X, et al. Bone metastasis pattern in initial metastatic breast cancer: a population-based study. Cancer Manag Res. 2018;10:287–295. doi: 10.2147/CMAR.S155524.
   PubMed Web of Science ®Google Scholar
• Plunkett TA, Smith P, Rubens RD. Risk of complications from bone metastases in breast cancer. implications for management. Eur J Cancer. 2000;36(4):476–482. doi: 10.1016/s0959-8049(99)00331-7.
   PubMed Web of Science ®Google Scholar
• D’Oronzo S, Coleman R, Brown J, et al. Metastatic bone disease: pathogenesis and therapeutic options: up-date on bone metastasis management. J Bone Oncol. 2019;15:004–004. doi: 10.1016/j.jbo.2018.10.004.
   PubMed Web of Science ®Google Scholar
• Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment. CA Cancer J Clin. 2017;67(3):194–232. doi: 10.3322/caac.21397.
   PubMed Web of Science ®Google Scholar
• Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res. 2006;12(20 Pt 2):6243s–6249s. doi: 10.1158/1078-0432.CCR-06-0931.
   PubMed Web of Science ®Google Scholar
• Liu D, Wu J, Lin C, et al. Breast subtypes and prognosis of breast cancer patients with initial bone metastasis: a population-based study. Front Oncol. 2020;10:580112. doi: 10.3389/fonc.2020.580112.
   PubMed Web of Science ®Google Scholar
• Mou H, Wang Z, Zhang W, et al. Clinical features and serological markers risk model predicts overall survival in patients undergoing breast cancer and bone metastasis surgeries. Front Oncol. 2021;11:693689. doi: 10.3389/fonc.2021.693689.
   PubMed Web of Science ®Google Scholar
• Li W, Xiao Y, Xu X, et al. A novel nomogram and risk classification system predicting the cancer-specific mortality of patients with initially diagnosed metastatic cutaneous melanoma. Ann Surg Oncol. 2021;28(7):3490–3500. doi: 10.1245/s10434-020-09341-5.
   PubMed Web of Science ®Google Scholar
• Huang XT, Huang CS, Liu C, et al. Development and validation of a new nomogram for predicting clinically relevant postoperative pancreatic fistula after pancreatoduodenectomy. World J Surg. 2021;45(1):261–269. doi: 10.1007/s00268-020-05773-y.
   PubMed Web of Science ®Google Scholar
• Hou N, Yi J, Wang Z, et al. Development and validation of a risk stratification nomogram for predicting prognosis in bone metastatic breast cancer: a population-based study. Medicine (Baltimore). 2021;100(6):e24751. doi: 10.1097/MD.0000000000024751.
   PubMed Web of Science ®Google Scholar
• Tu Q, Hu C, Zhang H, et al. Establishment and validation of novel clinical prognosis nomograms for luminal a breast cancer patients with bone metastasis. Biomed Res Int. 2020;2020:1972064. doi: 10.1155/2020/1972064.
   PubMed Web of Science ®Google Scholar
• Mao JR, Lan KQ, Liu SL, et al. Can the prognosis of individual patients with nasopharyngeal carcinoma be predicted using a routine blood test at admission? Radiother Oncol. 2023;179:109445. doi: 10.1016/j.radonc.2022.109445.
   PubMed Web of Science ®Google Scholar
• Ma C, Wang N, Ma H, et al. Serum gamma-glutamyl transpeptidase-to-platelet ratio (GPR) can predict the prognosis of hepatocellular carcinoma: a meta-analysis and systematic review. Transl Cancer Res. 2022;11(4):745–753. doi: 10.21037/tcr-21-2559.
   PubMed Web of Science ®Google Scholar
• Peng X, Huang Y, Fu H, et al. Prognostic value of blood urea nitrogen to serum albumin ratio in intensive care unit patients with lung cancer. Int J Gen Med. 2021;14:7349–7359. doi: 10.2147/IJGM.S337822.
   PubMed Web of Science ®Google Scholar
• Jokela EMK, Kauppila JH. Preoperative hemoglobin count and prognosis of esophageal cancer, a population-based nationwide study in Finland. Eur J Surg Oncol. 2022;48(3):548–552. doi: 10.1016/j.ejso.2021.08.020.
   PubMed Web of Science ®Google Scholar
• Zengel B, Kilic M, Tasli F, et al. Breast cancer patients with isolated bone metastases and oligometastatic bone disease show different survival outcomes. Sci Rep. 2021;11(1):20175. doi: 10.1038/s41598-021-99726-7.
   PubMed Web of Science ®Google Scholar
• Jones CM, Athanasiou T. Summary receiver operating characteristic curve analysis techniques in the evaluation of diagnostic tests. Ann Thorac Surg. 2005;79(1):16–20. doi: 10.1016/j.athoracsur.2004.09.040.
   PubMed Web of Science ®Google Scholar
• Cook NR. Use and misuse of the receiver operating characteristic curve in risk prediction. Circulation. 2007;115(7):928–935. doi: 10.1161/CIRCULATIONAHA.106.672402.
   PubMed Web of Science ®Google Scholar
• Bongers MER, Karhade AV, Setola E, et al. How does the skeletal oncology research group algorithm’s prediction of 5-year survival in patients with chondrosarcoma ­perform on international validation? Clin Orthop Relat Res. 2020;478(10):2300–2308. doi: 10.1097/CORR.0000000000001305.
   PubMed Web of Science ®Google Scholar
• Vernerey D, Huguet F, Vienot A, et al. Prognostic nomogram and score to predict overall survival in locally advanced untreated pancreatic cancer (PROLAP). Br J Cancer. 2016;115(3):281–289. doi: 10.1038/bjc.2016.212.
   PubMed Web of Science ®Google Scholar
• Harbeck N. Breast cancer is a systemic disease optimally treated by a multidisciplinary team. Nat Rev Dis Primers. 2020;6(1):30. doi: 10.1038/s41572-020-0167-z.
   PubMed Web of Science ®Google Scholar
• Li X, Zhang X, Liu J, et al. Prognostic factors and survival according to tumour subtype in women presenting with breast cancer bone metastases at initial diagnosis: a SEER-based study. BMC Cancer. 2020;20(1):1102. doi: 10.1186/s12885-020-07593-8.
   PubMed Web of Science ®Google Scholar
• Lobbezoo DJ, van Kampen RJ, Voogd AC, et al. Prognosis of metastatic breast cancer subtypes: the hormone receptor/HER2-positive subtype is associated with the most favorable outcome. Breast Cancer Res Treat. 2013;141(3):507–514. doi: 10.1007/s10549-013-2711-y.
   PubMed Web of Science ®Google Scholar
• Bertho M, Fraisse J, Patsouris A, et al. Real-life prognosis of 5041 bone-only metastatic breast cancer patients in the multicenter national observational ESME program. Ther Adv Med Oncol. 2021;13:1758835920987657. doi: 10.1177/1758835920987657.
   Web of Science ®Google Scholar
• Turner NC, Finn RS, Martin M, et al. Clinical considerations of the role of palbociclib in the management of advanced breast cancer patients with and without visceral metastases. Ann Oncol. 2018;29(3):669–680. doi: 10.1093/annonc/mdx797.
   PubMed Web of Science ®Google Scholar
• Lyu X, Luo B. Prognostic factors and survival prediction in HER2-positive breast cancer with bone metastases: a retrospective cohort study. Cancer Med. 2021;10(22):8114–8126. doi: 10.1002/cam4.4326.
   PubMed Web of Science ®Google Scholar
• Wang L, Lo CH, He X, et al. Risk factor profiles differ for cancers of different regions of the Colorectum. Gastroenterology. 2020;159(1):241–256.e13. doi: 10.1053/j.gastro.2020.03.054.
   PubMed Web of Science ®Google Scholar
• Diakos CI, Charles KA, McMillan DC, et al. Cancer-related inflammation and treatment effectiveness. Lancet Oncol. 2014;15(11):e493–e503. doi: 10.1016/S1470-2045(14)70263-3.
   PubMed Web of Science ®Google Scholar
• Terzić J, Grivennikov S, Karin E, et al. Inflammation and Colon cancer. Gastroenterology. 2010;138(6):2101–2114.e5. doi: 10.1053/j.gastro.2010.01.058.
   PubMed Web of Science ®Google Scholar
• Suzuki Y, Okabayashi K, Hasegawa H, et al. Comparison of preoperative inflammation-based prognostic scores in patients with colorectal cancer. Ann Surg. 2018;267(3):527–531. doi: 10.1097/SLA.0000000000002115.
   PubMed Web of Science ®Google Scholar
• Liang L, Liu F, Yang W, et al. Combined mean corpuscular hemoglobin, fibrinogen, and albumin (MF-A) is a Novel prognostic marker in patients with resectable esophageal squamous cell carcinoma. Ann Surg Oncol. 2022;29(9):5626–5633. doi: 10.1245/s10434-022-11415-5.
   PubMed Web of Science ®Google Scholar
• Qu X, Zhang T, Ma H, et al. Lower mean corpuscular hemoglobin concentration is associated with unfavorable prognosis of resected lung cancer. Future Oncol. 2014;10(14):2149–2159. doi: 10.2217/fon.14.121.
   PubMed Web of Science ®Google Scholar
• Zheng YZ, Dai SQ, Li W, et al. Prognostic value of preoperative mean corpuscular volume in esophageal squamous cell carcinoma. World J Gastroenterol. 2013;19(18):2811–2817. doi: 10.3748/wjg.v19.i18.2811.
   PubMed Web of Science ®Google Scholar
• Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–674. doi: 10.1016/j.cell.2011.02.013.
   PubMed Web of Science ®Google Scholar
• ] Lv GY, An L, Sun XD, et al. Pretreatment albumin to globulin ratio can serve as a prognostic marker in human cancers: a meta-analysis. Clin Chim Acta. 2018;476:81–91. doi: 10.1016/j.cca.2017.11.019.
   PubMed Web of Science ®Google Scholar
• Soeters PB, Wolfe RR, Shenkin A. Hypoalbuminemia: Pathogenesis and clinical significance. JPEN J Parenter Enteral Nutr. 2019;43(2):181–193. doi: 10.1002/jpen.1451.
   PubMed Web of Science ®Google Scholar
• Ding J, Karp JE, Emadi A. Elevated lactate dehydrogenase (LDH) can be a marker of immune suppression in cancer: interplay between hematologic and solid neoplastic clones and their microenvironments. Cancer Biomark. 2017;19(4):353–363. doi: 10.3233/CBM-160336.
   PubMed Web of Science ®Google Scholar
• Petrelli F, Cabiddu M, Coinu A, et al. Prognostic role of lactate dehydrogenase in solid tumors: a systematic ­review and meta-analysis of 76 studies. Acta Oncol. 2015;54(7):961–970. doi: 10.3109/0284186X.2015.1043026.
   PubMed Web of Science ®Google Scholar
• Roxburgh CS, McMillan DC. Role of systemic inflammatory response in predicting survival in patients with primary operable cancer. Future Oncol. 2010;6(1):149–163. doi: 10.2217/fon.09.136.
   PubMed Web of Science ®Google Scholar
• Viganó A, Bruera E, Jhangri GS, et al. Clinical survival predictors in patients with advanced cancer. Arch Intern Med. 2000;160(6):861–868. doi: 10.1001/archinte.160.6.861.
   PubMed Web of Science ®Google Scholar
• Meng X, Wang X, Jiang C, et al. Correlation analysis of lymphocyte-monocyte ratio with pathological complete response and clinical prognosis of neoadjuvant chemotherapy in patients with breast cancer. Transl Oncol. 2022;18:101355. doi: 10.1016/j.tranon.2022.101355.
   PubMed Web of Science ®Google Scholar
• Zhang Z, Lin Q, Chen Y, et al. Prognostic evaluation of metastasis-related lymphocyte/monocyte ratio in stage I-III breast cancer receiving chemotherapy. Front Oncol. 2021;11:782383. doi: 10.3389/fonc.2021.782383.
   PubMed Web of Science ®Google Scholar
• Li J, Chen S, Peng S, et al. Prognostic nomogram for patients with nasopharyngeal carcinoma incorporating hematological biomarkers and clinical characteristics. Int J Biol Sci. 14(5):549–556. 10.7150/ijbs.24374
   PubMed Web of Science ®Google Scholar
• Sun ZQ, Xu YY. Medical statistics (4th edition) [M]. Beijing: People’s Medical Publishing House; 2016. p. 293.
   Google Scholar
• Li M, Yao H, Zhang P, et al. Development and validation of a [18F]FDG PET/CT-based radiomics nomogram to predict the prognostic risk of pretreatment diffuse large B cell lymphoma patients. Eur Radiol. 2023;33(5):3354–3365. doi: 10.1007/s00330-022-09301-5IF:.7.034 Q1.
   PubMed Web of Science ®Google Scholar
• Zhao J, Li D, Xie S, et al. Nomogram for predicting prognosis of patients with metastatic melanoma after immunotherapy: a Chinese population-based analysis. Front Immunol. 2022;13:1083840. doi: 10.3389/fimmu.2022.1083840IF:.8.786 Q1.
   PubMed Web of Science ®Google Scholar